Table 6.
Outcome measures
|
Sample groups
|
Baseline
|
One-month
|
P value
|
Effectiveness size
|
Power
|
Total BAT12 score | VR (n = 23), mean (SD) | 27.24 (6.99) | 29.13 (7.25) | 0.625 | 0.2634 | 0.1601 |
TAU (n = 17), mean (SD) | 25.67 (7.00) | 26.94 (7.64) | 0.602 | 0.1708 | 0.0792 | |
VR vs TAU1 | - | - | 0.369 | 0.2899 | 0.1397 | |
Item 1 | VR (n = 23), mean (SD) | 3.41 (1.79) | 2.78 (1.54) | 0.157 | 0.195 | 0.9746 |
TAU (n = 17), mean (SD) | 2.19 (1.54) | 3.19 (1.76) | 0.075 | 0.307 | 0.5218 | |
VR vs TAU1 | - | - | 0.408 | 0.136 | 0.9721 | |
Item 2 | VR (n = 23), mean (SD) | 3.91 (1.11) | 3.52 (1.31) | 0.302 | 0.145 | 0.9953 |
TAU (n = 17), mean (SD) | 3.67 (1.32) | 3.81 (1.28) | 0.794 | 0.0453 | 0.9973 | |
VR vs TAU1 | - | - | 0.432 | 0.132 | 0.9748 | |
Item 3 | VR (n = 23), mean (SD) | 1.18 (0.39) | 1.22 (0.42) | 0.795 | 0.0504 | 0.9999 |
TAU (n = 17), mean (SD) | 1.10 (0.30) | 1.00 (0) | 0.624 | 0.206 | 0.8663 | |
VR vs TAU1 | - | - | 0.253 | 0.316 | 0.4992 | |
Item 4 | VR (n = 23), mean (SD) | 1.85 (0.93) | 1.74 (0.62) | 0.916 | 0.0151 | 1 |
TAU (n = 17), mean (SD) | 2.29 (0.90) | 2.00 (0.73) | 0.391 | 0.151 | 0.9538 | |
VR vs TAU1 | - | - | 0.304 | 0.183 | 0.9212 | |
Item 5 | VR (n = 23), mean (SD) | 2.03 (1.06) | 2.04 (0.88) | 0.801 | 0.0351 | 1 |
TAU (n = 17), mean (SD) | 1.81 (1.17) | 1.94 (1.18) | 0.646 | 0.0824 | 0.9918 | |
VR vs TAU1 | - | - | 0.458 | 0.126 | 0.9783 | |
Item 6 | VR (n = 23), mean (SD) | 2.06 (0.95) | 2.09 (1.12) | 0.961 | 0.0069 | 1 |
TAU (n = 17), mean (SD) | 1.81 (1.08) | 2.06 (1.29) | 0.581 | 0.098 | 0.9873 | |
VR vs TAU1 | - | - | 0.797 | 0.0433 | 0.9981 |
Virtual reality vs treatment as usual comparison at one-month.
VR: Virtual reality; TAU: Treatment as usual; BAT: Burnout Assessment Tool.